Latest & greatest articles for prednisolone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prednisolone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prednisolone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prednisolone

61. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial.

Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. 11081531 2000 11 17 2000 11 30 2015 06 16 0140-6736 356 9240 2000 Oct 28 Lancet (London, England) Lancet Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. 1480-5 Some patients with chronic obstructive pulmonary disease (COPD) respond to corticosteroid therapy. Whether these patients (...) have different airway pathology from other COPD patients is unclear. We tested the hypothesis that response to prednisolone is related to the presence of eosinophilic airway inflammation. We did a randomised, double-blind, crossover trial. Patients who had COPD treated with bronchodilators only were assigned placebo and 30 mg prednisolone daily for 2 weeks each, in a random order, separated by a 4-week washout period. Before and after each treatment period, we assessed patients with spirometry

Lancet2000

62. Prednisolone Treatment of Respiratory Syncytial Virus Infection: A Randomized Controlled Trial of 147 Infants.

Prednisolone Treatment of Respiratory Syncytial Virus Infection: A Randomized Controlled Trial of 147 Infants. PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club1999

63. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis.

A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. 10528036 1999 10 26 1999 10 26 2013 11 21 0028-4793 341 17 1999 Oct 21 The New England journal of medicine N. Engl. J. Med. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. 1264-9 Patients with idiopathic pulmonary fibrosis have progressive scarring of the lung (...) and usually die within four to five years after symptoms develop. Treatment with oral glucocorticoids is often ineffective. We conducted an open, randomized trial of treatment with a combination of interferon gamma-1b, which has antifibrotic properties, and an oral glucocorticoid. We studied 18 patients with idiopathic pulmonary fibrosis who had not had responses to glucocorticoids or other immunosuppressive agents. Nine patients were treated for 12 months with oral prednisolone alone (7.5 mg daily, which

NEJM1999

64. Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone

Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone Cost-effectiveness and cost-utility of combination therapy in early rheumatoid (...) arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone Verhoeven A C, Bibo J C, Boers M, Engel G L, van der Linden S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health

NHS Economic Evaluation Database.1998

65. Randomized double blind placebo controlled trial of prednisolone in children admitted to hospital with respiratory syncytial virus bronchiolitis

Randomized double blind placebo controlled trial of prednisolone in children admitted to hospital with respiratory syncytial virus bronchiolitis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club1997

66. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.

Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. 9251634 1997 11 24 1997 11 24 2016 11 24 0140-6736 350 9074 1997 Aug 02 Lancet (London, England) Lancet Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. 309-18 The value of intensive combination therapy in early rheumatoid arthritis is unproven (...) . In a multicentre, double-blind, randomised trial (COBRA), we compared the combination of sulphasalazine (2 g/day), methotrexate (7.5 mg/week), and prednisolone (initially 60 mg/day, tapered in 6 weekly steps to 7.5 mg/day) with sulphasalazine alone. 155 patients with early rheumatoid arthritis (median duration 4 months) were randomly assigned combined treatment (76) or sulphasalazine alone (79). Prednisolone and methotrexate were tapered and stopped after 28 and 40 weeks, respectively. The main outcomes were

Lancet1997

67. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster.

A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. 8114860 1994 03 31 1994 03 31 2013 11 21 0028-4793 330 13 1994 Mar 31 The New England journal of medicine N. Engl. J. Med. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. 896-900 Acyclovir given for 7 to 10 days is of proved benefit in acute herpes zoster, but studies of its effectiveness in preventing (...) postherpetic neuralgia have had conflicting results. The role of corticosteroids in the treatment of herpes zoster is also controversial. We conducted a double-blind, controlled trial in patients with acute herpes zoster to determine whether either 21 days of acyclovir therapy or the addition of prednisolone offered any improvement over 7 days of acyclovir therapy. Patients with a rash of less than 72 hours' duration were assigned to receive acyclovir (800 mg orally, five times daily) for 7 days

NEJM1994

68. A comparison of budesonide with prednisolone for active Crohn's disease.

A comparison of budesonide with prednisolone for active Crohn's disease. 8078530 1994 10 06 1994 10 06 2013 11 21 0028-4793 331 13 1994 Sep 29 The New England journal of medicine N. Engl. J. Med. A comparison of budesonide with prednisolone for active Crohn's disease. 842-5 Patients with active Crohn's disease are often treated with corticosteroids, but the treatment has many side effects. Budesonide is a potent, well-absorbed corticosteroid, but because of a high rate of first-pass metabolism (...) in the liver, its systemic bioavailability is low. We conducted a randomized, double-blind, 10-week trial comparing the efficacy and safety of an oral controlled-release form of budesonide with the efficacy and safety of prednisolone in 176 patients with active ileal or ileocecal Crohn's disease (88 patients in each treatment group). The dose of budesonide was 9 mg per day for eight weeks and then 6 mg per day for two weeks. The dose of prednisolone was 40 mg per day for two weeks, after which

NEJM1994

69. Placebo-controlled trial of prednisolone in children intubated for croup.

Placebo-controlled trial of prednisolone in children intubated for croup. 1356176 1992 10 22 1992 10 22 2015 06 16 0140-6736 340 8822 1992 Sep 26 Lancet (London, England) Lancet Placebo-controlled trial of prednisolone in children intubated for croup. 745-8 Many studies have attempted to find out whether steroid treatment is beneficial in children with croup, but the results have been inconclusive. We have done a prospective placebo-controlled study of the effect of prednisolone on two clinical (...) endpoints--the duration of intubation and the need for reintubation. Reasons for exclusion were age under 6 months, congenital airway anomalies, and previous intubation. 70 eligible children were randomly assigned treatment with prednisolone 1 mg/kg (n = 38) or placebo (n = 32) every 12 h given by nasogastric tube until 24 h after extubation. 11 (34%) placebo-treated and only 2 (5%) prednisolone-treated patients required reintubation after accidental or elective extubation (p = 0.004, Fisher's exact

Lancet1992

70. Short term linear growth in asthmatic children during treatment with prednisolone.

Short term linear growth in asthmatic children during treatment with prednisolone. 2202451 1990 09 28 1990 09 28 2017 02 19 0959-8138 301 6744 1990 Jul 21 BMJ (Clinical research ed.) BMJ Short term linear growth in asthmatic children during treatment with prednisolone. 145-8 To see whether small daily doses of prednisolone have any adverse effect on short term linear growth in children with mild asthma. Double blind, random order crossover trial of two dosages of prednisolone. During run (...) prednisolone daily given in divided dosage in the morning and evening. Growth of the lower leg as measured twice a week by knemometry. A significant reduction in mean growth velocity of the lower leg occurred in both prednisolone treatment periods. The mean difference between the run in period and the treatment period with 2.5 mg prednisolone daily was 0.63 mm/week (95% confidence interval 0.47 to 0.80 mm/week) and between the run in period and the treatment period with 5.0 mg prednisolone daily 0.57 mm

BMJ1990 Full Text: Link to full Text with Trip Pro

71. Comparison of prednisolone and placebo in subfertile men with antibodies to spermatozoa.

Comparison of prednisolone and placebo in subfertile men with antibodies to spermatozoa. 1967425 1990 02 20 1990 02 20 2015 06 16 0140-6736 335 8681 1990 Jan 13 Lancet (London, England) Lancet Comparison of prednisolone and placebo in subfertile men with antibodies to spermatozoa. 85-8 43 subfertile men with circulating antibodies to spermatozoa entered a double-blind crossover trial and received soluble prednisolone (20 mg twice daily on days 1-10 of the female partner's menstrual cycle (...) , followed by 5 mg on days 11 and 12) or matching placebo tablets for 9 months each. 9 pregnancies were produced by men during prednisolone treatment, compared with 2 by men randomised to placebo (although only 1 was actually taking the placebo). No serious complications were produced, although 60% of those receiving prednisolone experienced mild side-effects. Hendry W F WF Queen Charlotte's Hospital for Women, London, UK. Hughes L L Scammell G G Pryor J P JP Hargreave T B TB eng Clinical Trial

Lancet1990

72. Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness.

Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness. 2566790 1989 07 03 1989 07 03 2015 06 16 0140-6736 1 8649 1989 Jun 03 Lancet (London, England) Lancet Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness. 1246-50 In a prospective randomised trial, 620 patients who had Trypanosoma brucei gambiense trypanosomiasis with central nervous system involvement were treated either (...) with prednisolone plus melarsoprol or with melarsoprol only. 598 patients were evaluable: morbidity and death associated with melarsoprol-induced encephalopathy was reduced in patients who were given prednisolone. The two groups did not differ either in the incidence of other complications of melarsoprol therapy or in relapse rate after melarsoprol therapy. The cost of prednisolone would be outweighed by savings on the treatment of encephalopathies in such patients. Pepin J J University of Manitoba, Winnipeg

Lancet1989

73. Comparison of three immunosuppressive regimens in cadaver renal transplantation: long-term cyclosporine, short-term cyclosporine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine.

Comparison of three immunosuppressive regimens in cadaver renal transplantation: long-term cyclosporine, short-term cyclosporine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine. 3285215 1988 06 23 1988 06 23 2013 11 21 0028-4793 318 23 1988 Jun 09 The New England journal of medicine N. Engl. J. Med. Comparison of three immunosuppressive regimens in cadaver renal transplantation: long-term cyclosporine, short-term cyclosporine followed (...) by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine. 1499-507 We conducted a randomized trial in seven Australian hospitals of the efficacy and safety of three immunosuppressive regimens after first transplantation of a cadaver kidney: long-term cyclosporine, short-term (three months) cyclosporine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine. Patients assigned to long-term cyclosporine (n = 138) or short-term

NEJM1988

74. Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei.

Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei. 2901610 1988 10 27 1988 10 27 2015 06 16 0140-6736 2 8614 1988 Oct 01 Lancet (London, England) Lancet Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei. 759-64 240 patients with active tuberculous pericardial effusion received a 4-drug daily antituberculosis (...) regimen for 6 months and have been studied for 24 months or longer. Those willing were randomly allocated to open pericardial biopsy and complete drainage of pericardial fluid on admission or percutaneous pericardiocentesis as required. All patients were randomly allocated to prednisolone or matching placebo for the first 11 weeks, on a double-blind basis. Complete open drainage on admission abolished the need for pericardiocentesis (p less than 0.01) but did not influence the need for pericardiectomy

Lancet1988

75. Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei.

Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei. 2891992 1988 01 22 1988 01 22 2015 06 16 0140-6736 2 8573 1987 Dec 19 Lancet (London, England) Lancet Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei. 1418-22 In Transkei, 143 patients with active tuberculous constrictive pericarditis without significant pericardial effusion all received the same daily 6-month (...) antituberculosis regimen of streptomycin, isoniazid, rifampicin, and pyrazinamide for 14 weeks followed by isoniazid and rifampicin. They were randomly allocated to receive in addition either prednisolone or placebo for the first 11 weeks; the comparison was double-blind throughout treatment and follow-up. In the 114 patients assessable up to 24 months, improvement was significantly more rapid in the prednisolone group, as shown by the rate of fall in the mean pulse rate and the rate at which jugular venous

Lancet1987

76. Effect of a single oral dose of prednisolone in acute childhood asthma.

Effect of a single oral dose of prednisolone in acute childhood asthma. 2882288 1987 05 18 1987 05 18 2015 06 16 0140-6736 1 8538 1987 Apr 18 Lancet (London, England) Lancet Effect of a single oral dose of prednisolone in acute childhood asthma. 879-82 140 children of 184 with acute asthma entered a randomised double-blind trial of oral prednisolone (n = 67) compared with placebo (n = 73) administered soon after admission. The dose of prednisolone was 30 mg in children under 5, otherwise 60 mg (...) . All children also received salbutamol. All had moderate or severe dyspnoea. Initial evaluation was similar for both groups. On reassessment after a few hours 20 children in the prednisolone group were fit for discharge compared with only 2 in the placebo group. There were no early reattendances. Children remaining in hospital had a shorter median duration of stay and were less likely to require further steroid therapy if they had initially received prednisolone. In acute asthma the prompt use

Lancet1987

77. Prednisolone does not prevent post-herpetic neuralgia.

Prednisolone does not prevent post-herpetic neuralgia. 2885599 1987 08 18 1987 08 18 2015 06 16 0140-6736 2 8551 1987 Jul 18 Lancet (London, England) Lancet Prednisolone does not prevent post-herpetic neuralgia. 126-9 In a randomised, double-blind, controlled study of the effect of prednisolone on the development of post-herpetic neuralgia 78 patients with herpes zoster whose pain and exanthema had been present for less than 96 h were given 800 mg acyclovir five times daily for 7 days (...) and prednisolone in a total dose of 575 mg, starting with 40 mg daily in the first week and tapering off over the next 2 weeks. 18 (23%) of the patients had post-herpetic neuralgia at 6 months after the acute zoster, 9 (24.3%) having received prednisolone and 9 (22.5%) placebo. The 95% CI for the difference between the placebo and prednisolone groups in the proportion of patients having pain at 6 months was minus 17% to plus 20%. Prednisolone, however, relieved pain for the first 3 days. The 1-2 week interval

Lancet1987

78. Need for intravenous hydrocortisone in addition to oral prednisolone in patients admitted to hospital with severe asthma without ventilatory failure.

Need for intravenous hydrocortisone in addition to oral prednisolone in patients admitted to hospital with severe asthma without ventilatory failure. 2868207 1986 03 12 1986 03 12 2015 06 16 0140-6736 1 8474 1986 Jan 25 Lancet (London, England) Lancet Need for intravenous hydrocortisone in addition to oral prednisolone in patients admitted to hospital with severe asthma without ventilatory failure. 181-4 52 severely ill asthmatic patients requiring acute admission to hospital entered a double (...) -blind placebo-controlled trial to determine whether intravenous hydrocortisone given in addition to high-dose oral prednisolone and standard bronchodilator therapy accelerated recovery. Patients who had been given parenteral steroids before admission, by comparison with those who had not received such treatment, had been deteriorating for a shorter period before admission, had received more injected or nebulised bronchodilator therapy, and had higher admission peak flows. As judged by peak flow

Lancet1986

79. Effects of prednisolone in chronic airflow limitation.

Effects of prednisolone in chronic airflow limitation. 6146752 1984 08 30 1984 08 30 2015 06 16 0140-6736 2 8396 1984 Jul 28 Lancet (London, England) Lancet Effects of prednisolone in chronic airflow limitation. 193-6 A double-blind, randomised, placebo-controlled, crossover trial of prednisolone (40 mg daily for 14 days) was carried out in 43 patients with chronic airflow limitation (mean age 60 years, mean FEV1 1.02 litres, FEV1/FVC ratio 43.7%). Several subjective and objective variables (...) for response were measured. Significant improvements occurred with prednisolone in most variables measured, but improvements also occurred with placebo in some variables. The improvements with prednisolone in general wellbeing, 12 min walk distance, peak expiratory flow, FEV1, and relaxed vital capacity were significantly greater than those with placebo. Clinical assessment and assessment of atopic status did not reveal any feature of major predictive value for steroid responsiveness. A proportion

Lancet1984

80. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone.

Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. 6390194 1984 12 21 1984 12 21 2013 11 21 0028-4793 311 23 1984 Dec 06 The New England journal of medicine N. Engl. J. Med. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. 1464-70 A cooperative study was conducted to determine the efficacy of 30 days of treatment with either a glucocorticosteroid (prednisolone (...) ) or an anabolic steroid (oxandrolone) in moderate or severe alcoholic hepatitis. One hundred thirty-two patients with moderate disease and 131 with severe disease were randomly assigned to one of three treatments: prednisolone, oxandrolone, or placebo. During the 30 days, mortality in the groups receiving steroid therapy was not significantly different from mortality in the placebo group. Thirteen per cent of the moderately ill patients and 29 per cent of the severely ill patients died. Although neither

NEJM1984